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The publication, in this journal,1 of new lung 
function testing guidance from the Associa-
tion for Respiratory Technology & Physiology 
(ARTP), updates the original version from 
1994, published in conjunction with British 
Thoracic Society.2 This new guidance will 
undoubtedly be welcomed by physiologists 
and physicians and provides both a pragmatic 
and logical update, helping to inform and 
shape best practice in lung function depart-
ments across the UK. Contributors to this 
document are all senior widely experienced 
respiratory clinical physiologists±clinicians.
The document says a lot about how respi-
ratory medicine and physiology has changed 
in 25 years. We have seen several iterations of 
American Thoracic Society/European Respi-
ratory Society (ATS/ERS) technical stan-
dards for lung function testing,3–8 relatively 
dramatic changes in the training of respira-
tory physiology practitioners, improvements 
in testing innovation and technology as well as 
completely new approaches to the diagnosis 
of lung disease using imaging and other tech-
nology during this time. This statement thus 
very aptly provides a state- of- the- art update in 
the measurement and interpretation of lung 
function assessments.
While it does not always agree exactly 
with recent ATS/ERS technical standards 
documents,7 it has been written specifically 
with the UK health service in mind and as 
such adheres to much of the guidance and 
evidence provided by the ATS/ERS standards 
(eg, bronchodilatation section). Further-
more, this reflects the improved and higher 
level education and training standard in 
UK clinical respiratory physiology in recent 
decades, which encourages ‘thinking practi-
tioners’ rather than ‘following technicians’.9 
As such, the authors should be commended 
on improving the old guidance immensely 
by expanding the detail, adding the rationale 
for changes and thus helping those unfa-
miliar with the physiology/technology to 
understand why certain methods and criteria 
are used. This may in part be due to the fact 
that this document will have online material 
which means the size of the document is less 
critical than it was previously.
The document has a fine balance between 
making recommendations and encouraging 
the practitioner to decide for themselves 
which option to consider. This can be best 
seen in the height measurement sections. It 
is also not afraid to tackle controversial issues 
such as recording patient sex and not gender, 
and the use of lower limit of normal (LLN) 
and the fixed ratio for forced expiratory 
volume in 1 s/forced vital capacity (FEV1/
FVC) that have produced enormous overdi-
agnosis of chronic obstructive pulmonary 
disease, in the elderly, in the past.10
It has been written with an extensive list 
of citations which are included within text, 
which is a major improvement on the orig-
inal 1994 document (180 vs 17 in the orig-
inal). Moreover, there are many new sections 
(eg, patient consent, sniff nasal inspiratory 
pressure tests, paediatric testing and several 
sections have benefited from extended 
details, especially quality control, reference 
values, lung volume testing by all methods, 
blood gases and muscle function testing). 
Two changes which may be noticed by purists 
are (1) the change in repeatability for FEV1 
and FVC changing from 100 to 150 mL; and 
(2) the bronchodilator significant response 
becoming the change in Z- score. Both these 
changes are evidence based; the former may 
help primary care spirometry practitioners, 
whereas most lung function staff will usually 
achieve the 100 mL target in >90% of tests.10 
The use of Z- scores and LLN will help clin-
ical utilisation and interpretation of the bron-
chodilator response which has always been 
problematic in defining what’s a meaningful 
change.10
The document has evolved over 4 years 
and has had to accommodate the new global 
guidance that has been published in that 
time7 8 but even so, there was no anticipating 
the COVID-19 pandemic and particularly the 
changed perceptions and emerging evidence 
around infection control and personal 
protective equipment for lung function 
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staff. Fortunately, this has been addressed elsewhere by 
ARTP.11 12
While the calibration section could have been part of 
the quality control section, it actually fits logically in the 
practical guidance for testing. As a guide for writing clin-
ical operating procedures this document will be of great 
use to many departments as they achieve service accred-
itation (UK Accreditation Scheme, Improving Quality in 
Physiological Services) for lung function departments.
It is slightly disappointing that the guidance was not 
expanded to include other routine tests such as oscillom-
etry, airways resistance, fractional exhaled nitric oxide 
and Transfer factor for the lung for nitrohen monoxide 
(TLNO) measurements, as its initial statement to build 
on the innovation is not quite fulfilled, nevertheless it is 
an excellent document that needs to be used by clinical 
services as well as clinical trials and research projects. 
Some would argue that ATS/ERS technical standards 
cover this area well, but they are written for a larger audi-
ence and have to satisfy the North American markets 
(carbon monoxide diffusing capacity vs carbon monoxide 
transfer factor), and their standards are largely aimed at 
the equipment manufacturer’s so are more relevant to a 
global respiratory equipment market including the UK. 
These current ARTP standards are aimed at routine UK 
lung function service delivery and so are specific to our 
healthcare system. Any overlap with ATS/ERS standards 
should not act as a barrier to equipment manufacturers 
and ARTP have done well to harmonise those areas where 
they can.
Overall this document has achieved its remit and 
requires consideration by measurement practitioners, 
users of lung function and those who interpret the tests. 
Unfortunately, this may require the updating of other 
publications and guidelines such as quality- assured diag-
nostics spirometry guidance, ARTP handbooks and ARTP 
training course content, but such revision is never a bad 
thing for teachers or students. The ARTP leadership has 
delivered this guidance which continues to underline 
the importance of ensuring high- quality physiological 
measurement being undertaken in the UK and to help 
others to ensure quality- assured and robust diagnostics 
are undertaken to deliver the highest quality of care.
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